CymaBay Therapeutics Inc (CBAY) Director Kurt Von Emster Sells 211,124 Shares
CymaBay Therapeutics Inc (NASDAQ:CBAY) Director Kurt Von Emster sold 211,124 shares of the stock in a transaction on Friday, September 29th. The stock was sold at an average price of $8.09, for a total value of $1,707,993.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of CymaBay Therapeutics Inc (CBAY) traded down 4.47% on Monday, reaching $7.70. The company’s stock had a trading volume of 654,684 shares. The stock has a 50-day moving average of $6.59 and a 200 day moving average of $5.15. The stock’s market capitalization is $336.93 million. CymaBay Therapeutics Inc has a 52 week low of $1.15 and a 52 week high of $8.45.
CymaBay Therapeutics (NASDAQ:CBAY) last announced its earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.06). On average, analysts expect that CymaBay Therapeutics Inc will post ($0.82) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “CymaBay Therapeutics Inc (CBAY) Director Kurt Von Emster Sells 211,124 Shares” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.watchlistnews.com/cymabay-therapeutics-inc-cbay-director-kurt-von-emster-sells-211124-shares/1603892.html.
Several brokerages have recently issued reports on CBAY. Oppenheimer Holdings, Inc. began coverage on shares of CymaBay Therapeutics in a report on Friday, June 23rd. They set an “outperform” rating and a $8.00 price target for the company. HC Wainwright increased their price objective on shares of CymaBay Therapeutics from $7.00 to $12.00 and gave the stock a “buy” rating in a report on Monday, July 17th. Piper Jaffray Companies set a $7.00 price objective on shares of CymaBay Therapeutics and gave the stock a “buy” rating in a report on Monday, July 17th. Ifs Securities reiterated a “strong-buy” rating on shares of CymaBay Therapeutics in a research report on Monday, July 17th. Finally, Citigroup Inc. reiterated an “outperform” rating and issued a $15.00 price objective (up from $8.00) on shares of CymaBay Therapeutics in a research report on Thursday, July 20th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $12.69.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its position in CymaBay Therapeutics by 20.7% in the 2nd quarter. Vanguard Group Inc. now owns 991,633 shares of the biopharmaceutical company’s stock valued at $5,712,000 after purchasing an additional 170,126 shares during the last quarter. Boxer Capital LLC acquired a new position in CymaBay Therapeutics in the first quarter worth $3,342,000. Renaissance Technologies LLC boosted its stake in CymaBay Therapeutics by 97.6% in the first quarter. Renaissance Technologies LLC now owns 231,949 shares of the biopharmaceutical company’s stock worth $997,000 after purchasing an additional 114,549 shares in the last quarter. Ardsley Advisory Partners grew its holdings in shares of CymaBay Therapeutics by 66.2% during the second quarter. Ardsley Advisory Partners now owns 50,210 shares of the biopharmaceutical company’s stock worth $290,000 after purchasing an additional 20,000 shares during the last quarter. Finally, Marshall Wace North America L.P. bought a new stake in shares of CymaBay Therapeutics during the second quarter worth $242,000. Hedge funds and other institutional investors own 25.91% of the company’s stock.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.